









Markets
/
Stocks
/
nasdaq-hcm
/

HUTCHMED (China) Ltd

HCM

15.440USD

+0.130+0.85%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

13.47BMarket Cap

--P/E TTM



HUTCHMED (China) Ltd

15.440

+0.130+0.85%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of HUTCHMED (China) Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

HUTCHMED (China) Ltd's Score

Industry at a Glance

Industry Ranking

135 / 173

Overall Ranking

552 / 4682

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

21.215

Target Price

+38.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

HUTCHMED (China) Ltd Highlights

StrengthsRisks

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 47.79% year-on-year.

Undervalued

The company’s latest PE is 27.48, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 6.34M shares, decreasing 47.27% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.17K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Pharmaceuticals industry's average is 7.77. Its latest quarterly revenue reached 324.52M, representing a year-over-year increase of 6.36%, while its net profit experienced a year-over-year increase of 117.60%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

HUTCHMED (China) Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Pharmaceuticals industry's average is 7.19. Its current P/E ratio is 27.48, which is 1361.72% below the recent high of 401.72 and 0.67% above the recent low of 27.30.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 135/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.17, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for HUTCHMED (China) Ltd is 20.00, with a high of 40.40 and a low of 6.47.

Score

Industry at a Glance

Previous score

8.17

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

21.215

Target Price

+38.57%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

HUTCHMED (China) Ltd

HCM

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 5.54, which is lower than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 15.97 and the support level at 14.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.29

Change

-0.75

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.116

Neutral

RSI(14)

51.959

Neutral

STOCH(KDJ)(9,3,3)

64.218

Buy

ATR(14)

0.372

High Vlolatility

CCI(14)

144.522

Buy

Williams %R

23.810

Buy

TRIX(12,20)

-0.336

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

14.914

Buy

MA10

14.901

Buy

MA20

15.161

Buy

MA50

15.718

Sell

MA100

16.084

Sell

MA200

15.339

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 3.63%, representing a quarter-over-quarter decrease of 9.05%. The largest institutional shareholder is James Simons, holding a total of 129.00K shares, representing 0.07% of shares outstanding, with 31.61% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Schroder Investment Management (Singapore) Ltd.

1.77M

-5.23%

Allianz Global Investors Asia Pacific Limited

878.74K

-7.08%

Schroder Investment Management (Hong Kong) Ltd.

805.63K

-17.12%

State Street Investment Management (US)

328.79K

-2.40%

AIA Group Ltd

315.44K

Goldman Sachs & Company, Inc.

289.13K

+207.86%

M&G Investment Management Ltd.

259.62K

+0.36%

Su (Weiguo Ph.D.)

183.98K

Jane Street Capital, L.L.C.

175.96K

-20.82%

Amundi Asset Management, SAS

157.43K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Pharmaceuticals industry's average is 5.11. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.